ALBO - Albireo Pharma GAAP EPS of -$2.04 revenue of $8.2M August, 15 2022 04:10 PM Albireo Pharma Inc. Albireo Pharma press release ( NASDAQ: ALBO ): Q2 GAAP EPS of -$2.04. Revenue of $8.2M (+237.4% Y/Y). Bylvay(odevixibat) Q2 2022 net product revenue $5.9 million, June YTD 2022 $10.5 million For further details see: Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M